Ignite Creation Date:
2024-05-06 @ 12:16 AM
Last Modification Date:
2024-10-26 @ 10:47 AM
Study NCT ID:
NCT01531530
Status:
COMPLETED
Last Update Posted:
2021-04-30
First Post:
2011-10-26
Brief Title:
Safety and Efficacy Study of CVD 1208S a Live Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Safety Clinical Tolerance and Immunogenicity of CVD 1208S a Delta guaBA Delta Sen Delta Set Live Oral Shigella Flexneri 2a Vaccine Manufactured Using cGMP
Status:
COMPLETED
Status Verified Date:
2021-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether CVD 1208S a live attenuated oral vaccine is safe and effective in the prevention of Shigella infection
Detailed Description:
There are two purposes for conducting this Vaccine Study to evaluate an experimental vaccine called CVD 1208S Center for Vaccine Development 1208S 1 to learn whether CVD 1208S causes side effects and 2 to learn whether the CVD 1208S gives people immunity to Shigella
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Shigella CVD 28000 | OTHER | Center for Vaccine Development CVD UMB | None |